---
title: MDAI
description: 
published: true
date: 2026-01-30T09:33:19.098Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:55:47.645Z
---

[â—€è¿”å›](/è¯ç‰©/home.md)

# MDAI



| MDAI | |
| --- | --- |
| [![MDAI.png](/æ–‡ä»¶/MDAI.png)](/æ–‡ä»¶/MDAI.png) | |
| åŒ–å­¦å‘½å | |
| å¸¸ç”¨å | *MDAI* |
| å–ä»£åç§° | *5,6-äºšç”²åŒæ°§åŸº-2-æ°¨åŸºèŒš* |
| ç³»ç»Ÿåç§° | *6,7-Dihydro-5H-cyclopenta\[f\]\[1,3\]benzodioxol-6-amine* |
| ç‰©è´¨åˆ†ç±» | |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")* |
| åŒ–å­¦åˆ†ç±» | *[æ°¨åŸºèŒš](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æ°¨åŸºèŒšç±»ç‰©è´¨.md "Aminoindane") / [äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/äºšç”²åŒæ°§åŸºè‹¯ç±»ç‰©è´¨.md "MDxx")* |
| [ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| - **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹å“¦ã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚<br> | â‡£ [å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md#Oral "Routes of Administration") |
| | [å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#Threshold "Dosage classification") | 40 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#Light "Dosage classification") | 40 - 100 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#Common "Dosage classification") | 100 - 175 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#Strong "Dosage classification") | 175 - 300 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#Heavy "Dosage classification") | 300 mg + |
| | [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Total "Duration") | 4 - 6 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Onset "Duration") | 20 - 40 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Come_up "Duration") | 30 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Peak "Duration") | 2 - 2.5 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Offset "Duration") | 1 - 2 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#After_effects "Duration") | 1 - 6 å°æ—¶ |
| - **[å…è´£å£°æ˜](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…è´£å£°æ˜.md "Disclaimer")ï¼š** æœ¬ç«™çš„[å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[ç›¸å…³èµ„æº](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md "Network")ï¼Œä»…ä¾›æ•™è‚²ç”¨é€”ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§å–µã€‚ | |
| [è¯ç‰©è”ç”¨](#å±é™©è¯ç‰©è”ç”¨) | |
| é…’ç²¾ | âš ï¸ è°¨æ…è”ç”¨ |
| MXE | â›” ä¸¥ç¦è”ç”¨ |
| è§£ç¦»å‰‚ | âš ï¸ è°¨æ…è”ç”¨ |
| å³ç¾æ²™èŠ¬ | â›” ä¸¥ç¦è”ç”¨ |
| MDMA | ğŸ’” è”ç”¨å±é™© |
| å…´å¥‹å‰‚ | ğŸ’” è”ç”¨å±é™© |
| 25x-NBOMe | â›” ä¸¥ç¦è”ç”¨ |
| 25x-NBOH | â›” ä¸¥ç¦è”ç”¨ |
| æ›²é©¬å¤š | â›” ä¸¥ç¦è”ç”¨ |
| 5-ç¾Ÿè‰²èƒºå»ç”²è‚¾ä¸Šè…ºç´ å†æ‘„å–æŠ‘åˆ¶å‰‚ (SNRIs) | ğŸ’” è”ç”¨å±é™© |
| å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ (MAOIs) | â›” ä¸¥ç¦è”ç”¨ |
| è¡€æ¸…ç´ é‡Šæ”¾å‰‚ | â›” ä¸¥ç¦è”ç”¨ |
| é€‰æ‹©æ€§è¡€æ¸…ç´ å†æ‘„å–æŠ‘åˆ¶å‰‚ (SSRIs) | ğŸ’” è”ç”¨å±é™© |
| 5-HTP | â›” ä¸¥ç¦è”ç”¨ |

**5,6-äºšç”²åŒæ°§åŸº-2-æ°¨åŸºèŒš**ï¼ˆä¹Ÿç§°ä¸º **MDAI**ï¼‰æ˜¯ä¸€ç§è¾ƒå°‘è§çš„ã€å±äº[æ°¨åŸºèŒš](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æ°¨åŸºèŒšç±»ç‰©è´¨.md "Aminoindane")ç±»çš„æ–°å‹[å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")ã€‚å®ƒè¢«è®¤ä¸ºæ˜¯ä¸€ç§éç¥ç»æ¯’æ€§ä¸”é«˜åº¦é€‰æ‹©æ€§çš„[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")[é‡Šæ”¾å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md "Releasing agent")ï¼ˆSSRAï¼‰ï¼Œå¯¹[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")çš„å½±å“å¯ä»¥å¿½ç•¥ä¸è®¡å‘¢ã€‚

MDAI æ˜¯ç”±ç¾å›½è¯ç‰©åŒ–å­¦å®¶å’Œè¯ç†å­¦å®¶ [David E. Nichols](/wiki/David_E._Nichols "David E. Nichols") åœ¨ 1990 å¹´ä»£äºæ™®æ¸¡å¤§å­¦å¼€å‘çš„å“¦ã€‚\[*[æ¥æºè¯·æ±‚](/wiki/Citation_needed "Citation needed")*\] åœ¨ 2010 å¹´ä»£ï¼ŒMDAI ä¸åƒ [5-MAPB](/è¯ç‰©/5-MAPB.md "5-MAPB")ã€[5-APB](/è¯ç‰©/5-APB.md "5-APB") å’Œ [6-APB](/è¯ç‰©/6-APB.md "6-APB") è¿™æ ·çš„æ–°å‹[å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogens")ä¸€èµ·ä½œä¸º [MDMA](/è¯ç‰©/MDMA.md "MDMA") çš„åˆæ³•ç°è‰²å¸‚åœºæ›¿ä»£å“åœ¨åœ¨çº¿[ç ”ç©¶ç”¨åŒ–å­¦å“](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")å¸‚åœºä¸Šé”€å”®ã€‚ç›®å‰æ­£åœ¨ç ”ç©¶å°†å…¶ä½œä¸ºä¼ ç»Ÿå…±æƒ…å‰‚çš„æ½œåœ¨æ›¿ä»£å“ï¼Œç”¨äºæ²»ç–—ç„¦è™‘å’ŒæŠ‘éƒç­‰å¿ƒç†å¥åº·çŠ¶å†µå‘¢ã€‚\[*[æ¥æºè¯·æ±‚](/wiki/Citation_needed "Citation needed")*\]

[ä¸»è§‚æ•ˆåº”](/è¯æ•ˆ/home.md "Subjective effects")åŒ…æ‹¬[é•‡é™](/è¯æ•ˆ/é•‡é™.md "Sedation")ã€[è‚Œè‚‰æ¾å¼›](/è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md "Muscle relaxation")ã€[è§¦è§‰å¢å¼º](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md "Tactile enhancement")ã€[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/é•‡é™.md "Anxiety suppression")ã€[å…±æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Empathy, affection, and sociability enhancement")ä»¥åŠ[æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Euphoria")ã€‚æ®è¯´å®ƒäº§ç”Ÿçš„æ•ˆæœç±»ä¼¼äºå…¸å‹çš„å…±æƒ…å‰‚å¦‚ [MDMA](/è¯ç‰©/MDMA.md "MDMA") å’Œ [MDA](/è¯ç‰©/MDA.md "MDA")ï¼Œä½†ä¸å…·æœ‰åˆºæ¿€æ€§ã€‚æœ‰äººè®¤ä¸ºï¼Œç¼ºä¹å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ çš„æ´»æ€§é™åˆ¶äº†å®ƒäº§ç”Ÿæ˜æ˜¾çš„æŒ¯å¥‹ã€äº²ç¤¾ä¼šæˆ–[æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Euphoria")æ•ˆæœçš„èƒ½åŠ›ï¼Œä½†å¥½å¤„æ˜¯å‡å°‘äº†ç¥ç»æ¯’æ€§å’Œå‰¯ä½œç”¨å‘¢ã€‚ä¸è¿‡å˜›ï¼Œè¿˜éœ€è¦æ›´å¤šçš„ç ”ç©¶æ¥éªŒè¯è¿™äº›è¯´æ³•å“¦ã€‚

å…³äº MDAI çš„è¯ç†ç‰¹æ€§ã€ä»£è°¢å’Œæ¯’æ€§çš„æ•°æ®éå¸¸å°‘ï¼Œè€Œä¸”å®ƒçš„äººç±»ä½¿ç”¨å†å²ä¹Ÿå¾ˆæœ‰é™ã€‚å¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Harm reduction practices")å–µã€‚

ç›®å½•
--------

* [1 åŒ–å­¦](#åŒ–å­¦)
* [2 è¯ç†å­¦](#è¯ç†å­¦)
* [3 ä¸»è§‚æ•ˆåº”](#ä¸»è§‚æ•ˆåº”)
    + [3.1 **èº¯ä½“æ•ˆåº”**](#èº¯ä½“æ•ˆåº”)
    + [3.2 **è§†è§‰æ•ˆåº”**](#è§†è§‰æ•ˆåº”)
    + [3.3 **è®¤çŸ¥æ•ˆåº”**](#è®¤çŸ¥æ•ˆåº”)
    + [3.4 **å¬è§‰æ•ˆåº”**](#å¬è§‰æ•ˆåº”)
    + [3.5 **è¯æ•ˆæ®‹ä½™**](#è¯æ•ˆæ®‹ä½™)
    + [3.6 ä½“éªŒæŠ¥å‘Š](#ä½“éªŒæŠ¥å‘Š)
* [4 æ¯’æ€§å’Œå±å®³æ½œåŠ›](#æ¯’æ€§å’Œå±å®³æ½œåŠ›)
    + [4.1 ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›](#ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›)
    + [4.2 å±é™©è¯ç‰©è”ç”¨](#å±é™©è¯ç‰©è”ç”¨)
        - [4.2.1 è¡€æ¸…ç´ ç»¼åˆå¾é£é™©](#è¡€æ¸…ç´ ç»¼åˆå¾é£é™©)
* [5 æ³•å¾‹åœ°ä½](#æ³•å¾‹åœ°ä½)
* [6 å¦è§](#å¦è§)
* [7 å¤–éƒ¨é“¾æ¥](#å¤–éƒ¨é“¾æ¥)
    + [7.1 è®¨è®º](#è®¨è®º)
* [8 å‚è€ƒæ–‡çŒ®](#å‚è€ƒæ–‡çŒ®)

åŒ–å­¦
---------

MDAIï¼Œå³ 5,6-äºšç”²åŒæ°§åŸº-2-æ°¨åŸºèŒšï¼Œæ˜¯ä¸€ç§[æ°¨åŸºèŒš](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æ°¨åŸºèŒšç±»ç‰©è´¨.md "Aminoindane")ç±»çš„åˆæˆåˆ†å­ï¼Œåœ¨ç»“æ„ä¸Šä¸[è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Amphetamines")ç›¸ä¼¼ã€‚
å®ƒçš„ç‰¹ç‚¹æ˜¯è‹¯ä¸™èƒºä¸™çƒ·é“¾çš„ R3 æœ«ç«¯ç¢³åŸå­ä¸è‹¯ç¯ç»“åˆã€‚è¿™å°±äº§ç”Ÿäº†ä¸€ä¸ªèŒšåŸºå›¢ï¼Œè¿™æ˜¯ä¸€ä¸ªåŒ…å«ä¸æˆŠçƒ·ç¯èåˆçš„è‹¯ç¯çš„åŒç¯éƒ¨åˆ†ã€‚
MDAI åŒ…å«ä¸€ä¸ªæ°¨åŸº NH2ï¼Œç»“åˆåœ¨èŒšç¯çš„ R2 ä¸Šã€‚MDAI è¿˜åœ¨ R5 å’Œ R6 å¤„åŒ…å«ä¸¤ä¸ªæ°§å–ä»£ï¼Œç”±ä¸€ä¸ªäºšç”²åŸºæ¡¥è¿æ¥ï¼Œå½¢æˆä¸€ä¸ªäºšç”²åŒæ°§åŸºå›¢ã€‚

MDAI åœ¨ç»“æ„ä¸Šä¸ [2-AI](/è¯ç‰©/2-AI.md "2-AI") ç›¸å…³ï¼ŒåŒºåˆ«åœ¨äºå¤šäº†ä¸€ä¸ªäºšç”²åŒæ°§åŸºç¯ã€‚

è¯ç†å­¦
------------

| ![](/æ–‡ä»¶/Pill_bottle-o.png) | **æœ¬è¯ç†å­¦ç« èŠ‚[ä¸å®Œæ•´ã€‚](http://psychonautwiki.org/w/index.php?title=Special%3AWhatLinksHere&target=Template%3APharmacology&namespace=)**<br>*ä½ å¯ä»¥é€šè¿‡[è¡¥å……å®ƒ](https://psychonautwiki.org/w/index.php?title=MDAI&action=edit&section=)æ¥æä¾›å¸®åŠ©å–µã€‚* |
| --- | --- |

MDAI å·²è¢«è¯æ˜å¯ä»¥[æŠ‘åˆ¶è¡€æ¸…ç´ çš„å†æ‘„å–](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")ï¼Œå¹¶ä¸”å¯¹è¡€æ¸…ç´ [å—ä½“](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Receptor")å…·æœ‰é€‰æ‹©æ€§äº²å’ŒåŠ›ã€‚ç ”ç©¶è¡¨æ˜ï¼Œæ¥å— MDAI æ²»ç–—çš„åŠ¨ç‰©å¤§è„‘ä¸­[å•èƒºç±»ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Neurotransmitter")çš„ç»†èƒå¤–æµ“åº¦è¾ƒé«˜ï¼Œå…¶ä¸­æœ€æ˜¾è‘—çš„æ˜¯[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ã€‚\[*[æ¥æºè¯·æ±‚](/wiki/Citation_needed "Citation needed")*\]

ç›¸æ¯”ä¹‹ä¸‹ï¼ŒMDAI åœ¨é‡Šæ”¾è¡€æ¸…ç´ çš„æ•ˆåŠ›ä¸Šä¸ [MDA](/è¯ç‰©/MDA.md "MDA") ç›¸ä¼¼ï¼Œä½†æ˜æ˜¾ä½äº [MDMA](/è¯ç‰©/MDMA.md "MDMA")ã€‚[\[1\]](#cite_note-1) å®ƒçš„ä½œç”¨æœºåˆ¶æ˜¯åœ¨ç¥ç»é€’è´¨å®Œæˆä¼ é€’ç¥ç»å†²åŠ¨çš„åŠŸèƒ½åï¼ŒæŠ‘åˆ¶å…¶å†æ‘„å–å’Œé‡å¸æ”¶ï¼Œå®è´¨ä¸Šæ˜¯è®©å®ƒä»¬ç§¯ç´¯ã€è¢«é‡å¤åˆ©ç”¨å¹¶äº§ç”Ÿ[å…±æƒ…](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")æ•ˆåº”å‘¢ã€‚

ä¸»è§‚æ•ˆåº”
------------------

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª[**ä¸»è§‚æ•ˆåº”ç´¢å¼•**](/è¯æ•ˆ/home.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "PsychonautWiki") [è´¡çŒ®è€…](/wiki/Special:TopUsers "Special:TopUsers")ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬å“¦ã€‚*

*å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œè™½ç„¶é«˜å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**ä¹Ÿä¼šéšç€å‰‚é‡çš„å¢åŠ è€Œå˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **[èº¯ä½“æ•ˆåº”](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md)** ![Child.png](/æ–‡ä»¶/Child.png)
+ **[é•‡é™](/è¯æ•ˆ/é•‡é™.md "Sedation")** - MDAI å’Œ [MDMA](/è¯ç‰©/MDMA.md "MDMA") ä¹‹é—´æœ€å¤§çš„åŒºåˆ«åœ¨äºï¼ŒMDAI ä¸»è¦å¯¼è‡´ä¸­åº¦é•‡é™ï¼Œå› æ­¤å¯èƒ½ä¼šé˜»ç¢è·‘æ­¥ã€è·³èˆæˆ–æ”€çˆ¬ç­‰ä½“åŠ›æ´»åŠ¨ã€‚
+ **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Spontaneous physical sensations")** - MDAI çš„â€œèº¯ä½“å¿«æ„Ÿâ€å¯ä»¥æè¿°ä¸ºä¸€ç§ä¸­åº¦åˆ°æåº¦çš„æ¬£å¿«ã€æŸ”è½¯å’Œæ¸©æš–çš„åˆºç—›æ„Ÿï¼Œè¿™ç§æ„Ÿè§‰ä¼šåŒ…å›´å…¨èº«ã€‚åœ¨é«˜å‰‚é‡ä¸‹ï¼Œè¿™ç§æ„Ÿè§‰å¯èƒ½ä¼šå˜å¾—æåº¦ä»¤äººæ„‰æ‚¦ã€‚è¿™ç§æ„Ÿè§‰ä¼šæŒç»­å­˜åœ¨ï¼Œéšç€è¯æ•ˆå‘ä½œç¨³æ­¥ä¸Šå‡ï¼Œä¸€æ—¦è¾¾åˆ°[è¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Peak "Peak")å°±ä¼šè¾¾åˆ°æé™ã€‚
    - **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Physical euphoria")**
+ **[è§¦è§‰å¢å¼º](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md "Tactile enhancement")**
+ **[è§†ç‰©æŒ¯åŠ¨](/è¯æ•ˆ/è§†ç‰©æŒ¯åŠ¨.md "Vibrating vision")** - åœ¨é«˜å‰‚é‡ä¸‹ï¼Œäººçš„çœ¼çƒå¯èƒ½ä¼šå¼€å§‹ä¸ç”±è‡ªä¸»åœ°å¿«é€Ÿæ¥å›æ‘†åŠ¨ï¼Œå¯¼è‡´è§†åŠ›å˜å¾—æ¨¡ç³Šå¹¶æš‚æ—¶å¤±ç„¦ã€‚è¿™æ˜¯ä¸€ç§è¢«ç§°ä¸º[çœ¼çƒéœ‡é¢¤](http://en.wikipedia.org/wiki/Nystagmus)çš„æƒ…å†µã€‚
+ **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md "Increased perspiration")**
+ **[ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶](/è¯æ•ˆ/ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶.md "Temperature regulation suppression")**
+ **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md "Dehydration")** - å£å¹²å’Œè„±æ°´çš„æ„Ÿè§‰æ˜¯ MDAI çš„æ™®éä½“éªŒã€‚è¿™ç§æ•ˆåº”æ˜¯å¿ƒç‡å¢åŠ å’Œä»äº‹å‰§çƒˆä½“åŠ›æ´»åŠ¨çš„æç«¯åŠ¨æœºçš„äº§ç‰©ã€‚è™½ç„¶é¿å…è„±æ°´å¾ˆé‡è¦ï¼ˆç‰¹åˆ«æ˜¯åœ¨ç‚çƒ­çš„ç¯å¢ƒä¸­è·³èˆæ—¶ï¼‰ï¼Œä½†ä¹Ÿæ›¾æœ‰ä¸€äº›ç”¨æˆ·å› è¿‡é‡é¥®æ°´è€Œé­å—[æ°´ä¸­æ¯’](/wiki/Water_intoxication "Water intoxication")ï¼Œæ‰€ä»¥å»ºè®®ç”¨æˆ·åªéœ€å•œé¥®æ°´ï¼Œåƒä¸‡ä¸è¦è¿‡é‡é¥®æ°´å“¦ã€‚
+ **[æ’å°¿å›°éš¾](/è¯æ•ˆ/æ’å°¿å›°éš¾.md "Difficulty urinating")** - å°±åƒ MDMA ä¸€æ ·ï¼Œè¾ƒé«˜å‰‚é‡çš„ MDAI ä¼šå¯¼è‡´æ’å°¿å›°éš¾ã€‚è¿™ç§æ•ˆåº”æ˜¯å®Œå…¨æš‚æ—¶å’Œæ— å®³çš„ã€‚è¿™å¾ˆå¯èƒ½æ˜¯ç”±äºä¿ƒè¿›äº†[æŠ—åˆ©å°¿æ¿€ç´ ](https://en.wikipedia.org/wiki/Vasopressin)ï¼ˆADHï¼‰çš„é‡Šæ”¾ï¼Œè¿™ä¹Ÿæ˜¯ MDMA äº§ç”Ÿè¿™ç§å‰¯ä½œç”¨çš„æœºåˆ¶ã€‚æŠ—åˆ©å°¿æ¿€ç´ è´Ÿè´£è°ƒèŠ‚æ’å°¿ã€‚åªéœ€æ”¾æ¾å³å¯å‡è½»æ’å°¿å›°éš¾ï¼Œä½†ç”¨çƒ­æ¯›å·¾çƒ­æ•·ç”Ÿæ®–å™¨ä»¥ä½¿å…¶å˜æš–å¹¶ä¿ƒè¿›è¡€æ¶²æµåŠ¨å¯ä»¥æ˜¾è‘—ç¼“è§£ã€‚æœ‰äº›äººæŠ¥å‘Šè¯´ï¼Œä»…ä»…å¬æµæ°´çš„å£°éŸ³ä¹Ÿæœ‰å¸®åŠ©ï¼ˆæ¯”å¦‚æ°´é¾™å¤´ï¼‰ã€‚
+ **[æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢](/è¯æ•ˆ/æš‚æ—¶æ€§å‹ƒèµ·åŠŸèƒ½éšœç¢.md "Temporary erectile dysfunction")**

### **[è§†è§‰æ•ˆåº”](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)** ![Eye](/æ–‡ä»¶/Eye.png)

MDAI çš„è§†è§‰æ•ˆåº”ä»…åœ¨é«˜å‰‚é‡ä¸‹å‘ç”Ÿï¼Œæ®æŠ¥é“å…¶æ€§è´¨åªæ˜¯è½»å¾®çš„è¿·å¹»ã€‚è¿™äº›é€šå¸¸åŒ…æ‹¬ï¼š
+ **[è§†è§‰é”åº¦å¢å¼º](/è¯æ•ˆ/è§†è§‰é”åº¦å¢å¼º.md "Visual acuity enhancement")**
+ **[é¢œè‰²å¢å¼º](/è¯æ•ˆ/é¢œè‰²å¢å¼º.md "Colour enhancement")**
+ **[æ®‹å½±](/è¯æ•ˆ/æ®‹å½±.md "Tracers")**

### **[è®¤çŸ¥æ•ˆåº”](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** ![User.png](/æ–‡ä»¶/User.png)

MDAI çš„è®¤çŸ¥æ•ˆåº”å¯ä»¥åˆ†ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œéšç€å‰‚é‡çš„å¢åŠ é€æ¸åŠ å¼ºã€‚è®¸å¤šäººå°† MDAI çš„æ€»ä½“ç²¾ç¥çŠ¶æ€æè¿°ä¸ºä¸€ç§æ¬£å¿«æ„Ÿä»¥åŠçˆ±æˆ–å…±æƒ…çš„æ„Ÿè§‰ã€‚å®ƒåŒ…å«è®¸å¤šå…¸å‹çš„[å…±æƒ…](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogens")è®¤çŸ¥æ•ˆåº”ã€‚

å…¶ä¸­æœ€çªå‡ºçš„è®¤çŸ¥æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š


+ **[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/é•‡é™.md "Anxiety suppression")**
+ **[è®¤çŸ¥æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ¬£å¿«.md)** - å¼ºçƒˆçš„æƒ…ç»ªæ¬£å¿«æ„Ÿå’Œå¹¸ç¦æ„Ÿå­˜åœ¨äº MDAI ä½“éªŒä¸­ï¼Œè¿™æ˜¯[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")é‡Šæ”¾çš„ç›´æ¥ç»“æœã€‚
+ **[å…±æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Empathy, affection, and sociability enhancement")** - è¿™ç§ç‰¹å®šçš„æ•ˆåº”ä¸åƒ [MDMA](/è¯ç‰©/MDMA.md "MDMA") æˆ– [2C-B](/è¯ç‰©/2C-B.md "2C-B") é‚£æ ·æ˜æ˜¾ã€å¼ºå¤§å’Œå…·æœ‰æ²»ç–—ä½œç”¨ã€‚å®ƒæ˜¯ä»»ä½• MDAI ä½“éªŒä¸­æœ€æ˜æ˜¾å’Œå€¼å¾—æ³¨æ„çš„æ•ˆæœï¼Œå¹¶ä¸»å¯¼ç€ç²¾ç¥çŠ¶æ€ã€‚
+ **[éŸ³ä¹æ¬£èµå¢å¼º](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Increased music appreciation")**
+ **[æ²‰æµ¸æ„Ÿå¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Immersion enhancement")**
+ **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought deceleration")**
+ **[æ­£å¿µ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mindfulness")**
+ **[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")**

### **[å¬è§‰æ•ˆåº”](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md)** ![Volume-up.png](/æ–‡ä»¶/Volume-up.png)

+ **[å¬è§‰å¢å¼º](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory enhancement")**
+ **[å¬è§‰æ‰­æ›²](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory enhancement")**

### **è¯æ•ˆæ®‹ä½™** ![Aftereffects_(3).png](/æ–‡ä»¶/Aftereffects_(3).png)

åœ¨[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä½“éªŒçš„[è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Offset "Offset")æœŸé—´å‘ç”Ÿçš„æ•ˆæœï¼Œä¸[è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#Peak "Peak")æœŸé—´å‘ç”Ÿçš„æ•ˆæœç›¸æ¯”ï¼Œé€šå¸¸æ„Ÿè§‰æ˜¯æ¶ˆæå’Œä¸èˆ’æœçš„ã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œä¸‹å¤´â€ï¼ˆcomedownï¼‰ï¼Œæ˜¯å› ä¸º[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md "Neurotransmitter")è€—å°½è€Œå‘ç”Ÿçš„ã€‚å…¶å½±å“é€šå¸¸åŒ…æ‹¬ï¼š
+ **[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md "Anxiety")**
+ **[è®¤çŸ¥ç–²åŠ³](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive fatigue")**
+ **[æŠ‘éƒ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Depression")**
+ **[æ˜“æ€’](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Irritability")**
+ **[åŠ¨åŠ›æŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation suppression")**
+ **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought deceleration")**
+ **[æ¸…é†’](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")**

### ä½“éªŒæŠ¥å‘Š

ç›®å‰æˆ‘ä»¬çš„[ä½“éªŒæŠ¥å‘Šç´¢å¼•](/æŠ¥å‘Š/psychounautwiki/Experience_index "Experience index")ä¸­æ²¡æœ‰æè¿°è¯¥åŒ–åˆç‰©æ•ˆæœçš„è½¶äº‹æŠ¥å‘Šã€‚æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid ä½“éªŒåº“: MDAI](https://www.erowid.org/experiences/subs/exp_MDAI.shtml)


æ¯’æ€§å’Œå±å®³æ½œåŠ›
---------------------------

- ![](/æ–‡ä»¶/Ambulance2.png) **æœ¬æ¯’æ€§å’Œå±å®³æ½œåŠ›ç« èŠ‚æ˜¯ä¸€ä¸ª[å°èŠ‚ã€‚](http://psychonautwiki.org/w/index.php?title=Special%3AWhatLinksHere&target=Template%3AStub&namespace=)**å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**æå…¶é”™è¯¯**çš„ä¿¡æ¯ï¼ä½ å¯ä»¥é€šè¿‡[æ‰©å±•æˆ–æ›´æ­£å®ƒ](https://psychonautwiki.org/w/index.php?title=MDAI&action=edit)æ¥æä¾›å¸®åŠ©å–µã€‚
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹çš„è°ƒæŸ¥ç ”ç©¶å¹¶ä½¿ç”¨**[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")**å“¦ã€‚*

æ›´å¤šä¿¡æ¯ï¼š[ç ”ç©¶ç”¨åŒ–å­¦å“ Â§ æ¯’æ€§å’Œå±å®³æ½œåŠ›](/æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md#æ¯’æ€§å’Œå±å®³æ½œåŠ› "Research chemicals")

MDAI å’Œå…¶ä»–ç±»ä¼¼çš„è¯ç‰©å·²å¹¿æ³›ç”¨äºç§‘å­¦ç ”ç©¶ï¼Œå› ä¸ºå®ƒä»¬èƒ½å¤Ÿå¤åˆ¶ [MDMA](/è¯ç‰©/MDMA.md "MDMA") çš„è®¸å¤šæ•ˆæœï¼Œä½†ä¸ä¼šå¼•èµ·ç›¸å…³çš„[ç¥ç»æ¯’æ€§](/wiki/Neurotoxicity "Neurotoxicity")ã€‚
ç›®å‰è¿˜æ²¡æœ‰å…³äºå¿ƒè¡€ç®¡æ¯’æ€§çš„æµ‹è¯•ã€‚[\[2\]](#cite_note-2)[\[3\]](#cite_note-3)[\[4\]](#cite_note-4)[\[5\]](#cite_note-5)[\[6\]](#cite_note-6)[\[7\]](#cite_note-7)[\[8\]](#cite_note-8)

ç›®å‰æ²¡æœ‰å…³äº MDAI åœ¨äººç±»ä¸­çš„è‡´æ­»å‰‚é‡çš„ç§‘å­¦æ•°æ®ï¼Œç¡®åˆ‡çš„ä¸­æ¯’å‰‚é‡ä¹Ÿæ˜¯æœªçŸ¥çš„ã€‚ç”±äºå®ƒä½œä¸ºä¸€ç§[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")[å†æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")çš„ä½œç”¨ï¼Œè¿‡é‡æœç”¨è¿™ç§ç‰©è´¨å¾ˆå¯èƒ½å¯¼è‡´[è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¿™ç§ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚

### ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›

è™½ç„¶æ²¡æœ‰è¿›è¡Œæ­£å¼çš„ç ”ç©¶ï¼Œä½† MDAI å¯ä»¥è¢«è®¤ä¸ºå…·æœ‰ä¸€å®šçš„æˆç˜¾æ€§ï¼Œæ»¥ç”¨æ½œåŠ›è¾ƒä½ï¼Œè€Œä¸”ä¸å¤ªå¯èƒ½å¯¼è‡´å¤§å¤šæ•°ä½¿ç”¨è€…äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚
è¿™æ˜¯å› ä¸ºä¸ä¼ ç»Ÿçš„å…´å¥‹å‰‚ä¸åŒï¼ŒMDAI ä¸ä¼šå¢åŠ [å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")çš„æµ“åº¦ã€‚å¦‚æœå·²ç»å½¢æˆæˆç˜¾ï¼Œä¸€æ—¦çªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æ±‚å’Œ[æˆ’æ–­æ•ˆåº”](/æ–‡æ¡£/è¯ç‰©æˆ’æ–­ååº”.md "Withdrawal effects")ã€‚

éšç€é•¿æœŸå’Œåå¤ä½¿ç”¨ï¼Œä¼šå¯¹ MDAI çš„è®¸å¤šæ•ˆæœäº§ç”Ÿè€å—æ€§ã€‚
è¿™å¯¼è‡´ä½¿ç”¨è€…ä¸å¾—ä¸æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚
ä¹‹åï¼Œå¤§çº¦éœ€è¦ 3 - 7 å¤©è€å—æ€§æ‰èƒ½å‡åŠï¼Œ1 - 2 å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿æ°´å¹³ï¼ˆåœ¨æ²¡æœ‰è¿›ä¸€æ­¥æ‘„å…¥çš„æƒ…å†µä¸‹ï¼‰ã€‚

MDAI ä¸æ‰€æœ‰[å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogens")å­˜åœ¨äº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€æœç”¨ MDAI åï¼Œæ‰€æœ‰è¡€æ¸…ç´ èƒ½[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")çš„æ•ˆæœéƒ½ä¼šé™ä½å‘¢ã€‚

### å±é™©è¯ç‰©è”ç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨åˆ—å‡ºäº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸èƒ½ä¿è¯åŒ…å«æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹çš„è°ƒæŸ¥ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ï¼Œä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨æœç”¨çš„ã€‚ä¸€äº›åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

* **[25x-NBOMe](/è¯ç‰©/25I-NBOMe.md "25x-NBOMe") & [25x-NBOH](/è¯ç‰©/25B-NBOH.md "25x-NBOH")** - 25x ç±»åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§ï¼Œå¯¹èº«ä½“æœ‰å¾ˆå¤§è´Ÿæ‹…ã€‚åº”ä¸¥æ ¼é¿å…ä¸ MDAI è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md "Stimulation")å’Œå¿ƒè„è´Ÿæ‹…çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´[è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")ã€[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md "Vasoconstriction")ã€ææ…Œå‘ä½œã€[æ€ç»´å¾ªç¯](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought loops")ã€[ç™«ç—«å‘ä½œ](/è¯æ•ˆ/ç™«ç—«å‘ä½œ.md "Seizures")ï¼Œæç«¯æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
* **[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md "Alcohol")** - å°†é…’ç²¾ä¸[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ç»“åˆä½¿ç”¨å¯èƒ½å¾ˆå±é™©ï¼Œå› ä¸ºå­˜åœ¨æ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚ä¼šæ©ç›–é…’ç²¾çš„[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨ï¼Œè€Œå¤§å¤šæ•°äººæ˜¯ç”¨è¿™ç§ä½œç”¨æ¥è¯„ä¼°è‡ªå·±çš„é†‰é…’ç¨‹åº¦çš„ã€‚ä¸€æ—¦å…´å¥‹å‰‚è¯æ•ˆæ¶ˆé€€ï¼Œ[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨å°†ä¸å†å—å¯¹æŠ—ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œä½¿ç”¨è€…åº”ä¸¥æ ¼é™åˆ¶è‡ªå·±æ¯å°æ—¶åªå–ä¸€å®šé‡çš„é…’ç²¾ã€‚
* **[å³ç¾æ²™èŠ¬](/è¯ç‰©/å³ç¾æ²™èŠ¬.md "DXM")** - åº”é¿å…ä¸å³ç¾æ²™èŠ¬è”ç”¨ï¼Œå› ä¸ºå®ƒå…·æœ‰æŠ‘åˆ¶[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")å†æ‘„å–çš„ä½œç”¨ã€‚ä¸è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼ˆ[MDMA](/è¯ç‰©/MDMA.md "MDMA")ã€[ç”²åŸºé…®](/wiki/Methylone "Methylone")ã€[ç”²æ°§éº»é»„é…®](/è¯ç‰©/4-MMC.md "Mephedrone")ç­‰ï¼‰è”ç”¨æ—¶ï¼Œ[ææ…Œå‘ä½œ](/è¯æ•ˆ/ç„¦è™‘.md "Panic attacks")å’Œé«˜è¡€å‹å±è±¡æˆ–[è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ä¼šå¢åŠ ã€‚è¯·ä»”ç»†ç›‘æµ‹è¡€å‹å¹¶é¿å…å‰§çƒˆçš„ä½“åŠ›æ´»åŠ¨å“¦ã€‚
* **[MDMA](/è¯ç‰©/MDMA.md "MDMA")** - å½“å­˜åœ¨å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§ä½œç”¨éƒ½å¯èƒ½å¢åŠ ã€‚è¿˜å­˜åœ¨è¡€å‹è¿‡é«˜å’Œå¿ƒè„è´Ÿæ‹…ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
* **[MXE](/è¯ç‰©/MXE.md "MXE")** - ä¸€äº›æŠ¥å‘Šè¡¨æ˜ï¼Œä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹ï¼Œå¹¶å¢åŠ [èºç‹‚](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Psychosis")çš„é£é™©ã€‚
* **[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md "Dissociatives")** - è¿™ä¸¤ç±»ç‰©è´¨éƒ½æœ‰å¯¼è‡´[å¦„æƒ³](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusions")ã€[èºç‹‚](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Psychosis")çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™äº›é£é™©å¯èƒ½ä¼šæˆå€å¢åŠ ã€‚
* **[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")** - MDAI ä¸å…¶ä»–[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")å¦‚[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")è”ç”¨å¯èƒ½å¾ˆå±é™©ï¼Œå› ä¸ºå®ƒä»¬ä¼šå°†[å¿ƒç‡](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")å’Œ[è¡€å‹](/è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")æé«˜åˆ°å±é™©æ°´å¹³ã€‚
* **[æ›²é©¬å¤š](/è¯ç‰©/æ›²é©¬å¤š.md "Tramadol")** - å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«å‘ä½œé˜ˆå€¼[\[9\]](#cite_note-9)ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚
* **[MDMA](/è¯ç‰©/MDMA.md "MDMA")** - ä¸å…¶ä»–å…´å¥‹å‰‚è”ç”¨æ—¶ï¼ŒMDMA çš„ç¥ç»æ¯’æ€§ä½œç”¨å¯èƒ½ä¼šå¢åŠ ã€‚
* **[å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md "Cocaine")** - è¿™ç§ç»„åˆå¯èƒ½ä¼šå°†å¿ƒè„è´Ÿæ‹…å¢åŠ åˆ°å±é™©ç¨‹åº¦ã€‚

#### [è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")é£é™©

ä¸ä»¥ä¸‹ç‰©è´¨è”ç”¨ä¼šå¯¼è‡´å±é™©çš„é«˜[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")æ°´å¹³ã€‚[è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")éœ€è¦ç«‹å³å°±åŒ»ï¼Œå¦‚æœä¸æ²»ç–—å¯èƒ½ä¼šè‡´å‘½ã€‚

* **å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ (MAOIs)** - ä¾‹å¦‚[å¡çš®æœ¨](/wiki/Banisteriopsis_caapi "Banisteriopsis caapi")ã€[éª†é©¼è“¬](/wiki/Syrian_rue "Syrian rue")ã€è‹¯ä¹™è‚¼ã€å¸æ¥å‰å…°å’Œå—æ°¯è´èƒºã€‚[\[10\]](#cite_note-10)
* **è¡€æ¸…ç´ é‡Šæ”¾å‰‚** - ä¾‹å¦‚ [MDMA](/è¯ç‰©/MDMA.md "MDMA")ã€[4-FA](/è¯ç‰©/4-FA.md "4-FA")ã€[ç”²åŸºè‹¯ä¸™èƒº](/è¯ç‰©/ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")ã€[ç”²åŸºé…®](/wiki/Methylone "Methylone")å’Œ [Î±MT](/è¯ç‰©/Î±MT.md "Î‘MT")ã€‚
* **é€‰æ‹©æ€§è¡€æ¸…ç´ å†æ‘„å–æŠ‘åˆ¶å‰‚ (SSRIs)** - ä¾‹å¦‚è¥¿é…æ™®å…°å’Œèˆæ›²æ—
* **[5-ç¾Ÿè‰²èƒºå»ç”²è‚¾ä¸Šè…ºç´ å†æ‘„å–æŠ‘åˆ¶å‰‚ (SNRIs)](http://en.wikipedia.org/wiki/SNRIs "wikipedia:SNRIs")** - ä¾‹å¦‚[æ›²é©¬å¤š](/è¯ç‰©/æ›²é©¬å¤š.md "Tramadol")å’Œæ–‡æ‹‰æ³•è¾›
* **[5-HTP](/è¯ç‰©/5-HTP.md)**

æ³•å¾‹åœ°ä½
------------

* **å¥¥åœ°åˆ©**ï¼šæ ¹æ® NPSG (Neue-Psychoaktive-Substanzen-Gesetz Ã–sterreich)ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”® MDAI æ˜¯éæ³•çš„ã€‚\[*[æ¥æºè¯·æ±‚](/wiki/Citation_needed "Citation needed")*\]
* **å·´è¥¿**ï¼šæ ¹æ® Portaria SVS/MS nÂº 344ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”® MDAI æ˜¯éæ³•çš„ã€‚[\[11\]](#cite_note-11)
* **ä¸­å›½**ï¼šæˆªè‡³ 2015 å¹´ 10 æœˆï¼ŒMDAI åœ¨ä¸­å›½å±äºç®¡åˆ¶ç‰©è´¨ã€‚[\[12\]](#cite_note-12)
* **ä¸¹éº¦**ï¼šæˆªè‡³ 2015 å¹´ 9 æœˆï¼ŒMDAI åœ¨ä¸¹éº¦æ˜¯éæ³•çš„ã€‚[\[13\]](#cite_note-13)
* **å¾·å›½**ï¼šæˆªè‡³ 2016 å¹´ 11 æœˆ 26 æ—¥ï¼ŒMDAI å— NpSGï¼ˆ*æ–°ç²¾ç¥æ´»æ€§ç‰©è´¨æ³•*ï¼‰[\[14\]](#cite_note-14)ç®¡åˆ¶ã€‚[\[15\]](#cite_note-15) ä»¥æŠ•æ”¾å¸‚åœºä¸ºç›®çš„çš„ç”Ÿäº§å’Œè¿›å£ã€ç»™äºˆä»–äººä»¥åŠäº¤æ˜“å‡åº”å—åˆ°æƒ©ç½šã€‚æ‹¥æœ‰æ˜¯éæ³•çš„ï¼Œä½†ä¸ä¼šå—åˆ°å¤„ç½šã€‚[\[16\]](#cite_note-16)
* **æ—¥æœ¬**ï¼šè‡ª 2013 å¹´ 3 æœˆ 30 æ—¥èµ·ï¼ŒMDAI åœ¨æ—¥æœ¬å±äºç®¡åˆ¶ç‰©è´¨ã€‚[\[17\]](#cite_note-17)
* **ç‘å£«**ï¼šMDAI æ˜¯ Verzeichnis E ä¸­æ˜ç¡®åˆ—å‡ºçš„ç®¡åˆ¶ç‰©è´¨ã€‚è‡ª 2011 å¹´ 12 æœˆèµ·æˆä¸ºç®¡åˆ¶ç‰©è´¨ã€‚[\[18\]](#cite_note-18)
* **åœŸè€³å…¶**ï¼šMDAI è¢«å½’ç±»ä¸ºæ¯’å“ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£å‡å±éæ³•ã€‚[\[19\]](#cite_note-Bakanlar_Kurulu_Karar.C4.B1_-_Karar_Say.C4.B1s.C4.B1_:_2013.2F5742-19) [\[20\]](#cite_note-List_of_illegal_substances_for_law-20)
* **è‹±å›½**ï¼šæ ¹æ® 2016 å¹´ 5 æœˆ 26 æ—¥ç”Ÿæ•ˆçš„ã€Šç²¾ç¥æ´»æ€§ç‰©è´¨æ³•ã€‹ï¼Œç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£ MDAI æ˜¯éæ³•çš„ã€‚[\[21\]](#cite_note-21)

å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")
* [å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md "Entactogen")
* [MDMA](/è¯ç‰©/MDMA.md "MDMA")
* [6-APB](/è¯ç‰©/6-APB.md "6-APB")
* [2-AI](/è¯ç‰©/2-AI.md "2-AI")

å¤–éƒ¨é“¾æ¥
--------------

* [MDAI (Wikipedia)](https://en.wikipedia.org/wiki/MDAI)
* [MDAI (Erowid Vault)](https://www.erowid.org/chemicals/mdai/mdai.shtml)
* [MDAI (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=2149)

### è®¨è®º

* [The Big & Dandy MDAI Thread (Bluelight)](http://www.bluelight.org/vb/threads/434331-The-Big-amp-Dandy-MDAI-Thread)

å‚è€ƒæ–‡çŒ®
----------

1. [â†‘](#cite_ref-1) Johnson, M. P., Conarty, P. F., Nichols, D. E. (23 July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". *European Journal of Pharmacology*. **200** (1): 9â€“16. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0014-2999(91)90659-e](//doi.org/10.1016%2F0014-2999%2891%2990659-e). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999). 
2. [â†‘](#cite_ref-2) Nichols, D. E., Brewster, W. K., Johnson, M. P., Oberlender, R., Riggs, R. M. (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". *Journal of Medicinal Chemistry*. **33** (2): 703â€“710. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1021/jm00164a037](//doi.org/10.1021%2Fjm00164a037). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0022-2623](//www.worldcat.org/issn/0022-2623). 
3. [â†‘](#cite_ref-3) Nichols, D. E., Johnson, M. P., Oberlender, R. (January 1991). "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". *Pharmacology, Biochemistry, and Behavior*. **38** (1): 135â€“139. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0091-3057(91)90601-w](//doi.org/10.1016%2F0091-3057%2891%2990601-w). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-3057](//www.worldcat.org/issn/0091-3057). 
4. [â†‘](#cite_ref-4) MP, J., SP, F., ((R, O.)), DE, N. (1 May 1991). "Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)". *Journal of Medicinal Chemistry*. **34** (5): 1662â€“1668. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1021/JM00109A020](//doi.org/10.1021%2FJM00109A020). 
5. [â†‘](#cite_ref-5) Johnson, M. P., Huang, X. M., Nichols, D. E. (December 1991). "Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue". *Pharmacology, Biochemistry, and Behavior*. **40** (4): 915â€“922. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0091-3057(91)90106-c](//doi.org/10.1016%2F0091-3057%2891%2990106-c). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-3057](//www.worldcat.org/issn/0091-3057). 
6. [â†‘](#cite_ref-6) Nichols, D. E., Marona-Lewicka, D., Huang, X., Johnson, M. P. (1993). "Novel serotonergic agents". *Drug Design and Discovery*. **9** (3â€“4): 299â€“312. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1055-9612](//www.worldcat.org/issn/1055-9612). 
7. [â†‘](#cite_ref-7) Sprague, J. E., Johnson, M. P., Schmidt, C. J., Nichols, D. E. (25 October 1996). "Studies on the mechanism of p-chloroamphetamine neurotoxicity". *Biochemical Pharmacology*. **52** (8): 1271â€“1277. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/0006-2952(96)00482-0](//doi.org/10.1016%2F0006-2952%2896%2900482-0). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0006-2952](//www.worldcat.org/issn/0006-2952). 
8. [â†‘](#cite_ref-8) Cozzi, N. V., Frescas, S., Marona-Lewicka, D., Huang, X., Nichols, D. E. (March 1998). "Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential". *Pharmacology, Biochemistry, and Behavior*. **59** (3): 709â€“715. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/s0091-3057(97)00557-1](//doi.org/10.1016%2Fs0091-3057%2897%2900557-1). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0091-3057](//www.worldcat.org/issn/0091-3057). 
9. [â†‘](#cite_ref-9) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2): 63â€“67. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1937-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [163567183](//www.worldcat.org/oclc/163567183). 
10. [â†‘](#cite_ref-10) Gillman, P. K. (2005). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4): 434â€“441. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.png/langen-gb-20px-Lock-green.png.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1471-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0007-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647). 
11. [â†‘](#cite_ref-11) <http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7>
12. [â†‘](#cite_ref-12) å…³äºå°å‘ã€Šéè¯ç”¨ç±»éº»é†‰è¯å“å’Œç²¾ç¥è¯å“åˆ—ç®¡åŠæ³•ã€‹çš„é€šçŸ¥ | <http://www.sfda.gov.cn/WS01/CL0056/130753.html>
13. [â†‘](#cite_ref-13) "Lists of euphoriant substances subject to control in Denmark". The Danish Medicines Agency. September 2015. | <http://laegemiddelstyrelsen.dk/en/licensing/company-authorisations-and-registrations/euphoriant-substances/lists>
14. [â†‘](#cite_ref-14) ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 15, 2019. 
15. [â†‘](#cite_ref-15) ["Gesetz zur BekÃ¤mpfung der Verbreitung neuer psychoaktiver Stoffe"](https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518) (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 15, 2019. 
16. [â†‘](#cite_ref-16) ["Â§ 4 NpSG"](https://www.gesetze-im-internet.de/npsg/__4.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 15, 2019. 
17. [â†‘](#cite_ref-17) ["æ–°ãŸã«æŒ‡å®šã•ã‚ŒãŸæŒ‡å®šè–¬ç‰©ã®åç§°"](https://www.mhlw.go.jp/stf/houdou/2r985200000312nw-att/2r985200000312pd.pdf) (PDF, in Japanese). åšç”ŸåŠ´åƒçœ [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved on May 2, 2022.
18. [â†‘](#cite_ref-18) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
19. [â†‘](#cite_ref-Bakanlar_Kurulu_Karar.C4.B1_-_Karar_Say.C4.B1s.C4.B1_:_2013.2F5742_19-0) [*BaÅŸbakanlÄ±k MevzuatÄ± GeliÅŸtirme ve YayÄ±n Genel MÃ¼dÃ¼rlÃ¼ÄŸÃ¼*](https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm) 
20. [â†‘](#cite_ref-List_of_illegal_substances_for_law_20-0)  <https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf>
21. [â†‘](#cite_ref-21) [*Psychoactive Substances Act 2016*](https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted)